The Experience Matters. Let us show you why.
Contact us today.
Bart Cobert gives his pharmacovigilance point of view on a recent paper on FDA approval timelines and drug safety issues.
Read MoreWhat information should be examined in the study and work up of ADRs to determine whether the reaction is likely due to the drug or not.
Read MoreWe participate in safety reporting not only because it is required by law, but because we are HCPs whose first duty is always to protect the patient.
Read MoreExploring the role of the Medical Monitor in the clinical research process.
Read MoreFDA operates one of the largest and most complete databases of adverse events on drugs marketed in the US. FAERS data is now easily searchable online.
Read MoreMany US patients are obtaining drugs from online and foreign pharmacies. Bart Cobert examines this trend, and its impact on drug safety.
Read MoreAny time a pharma organization engages in social media monitoring, they have to be prepared to uncover potential adverse events. Here are 7 best practices for managing this process.
Read MoreClosely-tied Medical Information and Drug Safety departments, with a seamless adverse event intake and hand-off processs, offer better quality control, scalability and risk mitigation.
Read MoreFrank Pettinato discusses the FDA database which catalogs adverse event and product complaint info for foods, dietary supplements, and cosmetics.
Read MoreWhat’s Next: Practical Steps for Pharma's Increased Social Media Participation
Read MoreAs an industry leader in business process outsourcing, C3i Solutions delivers global, multi-channel engagement solutions. The Experience Matters. Let us show you why.
Contact Us